BioDelivery Sciences International (NASDAQ:BDSI) Downgraded by BidaskClub to Buy

BidaskClub cut shares of BioDelivery Sciences International (NASDAQ:BDSI) from a strong-buy rating to a buy rating in a research note issued to investors on Friday, BidAskClub reports.

Several other equities analysts have also recently commented on BDSI. Janney Montgomery Scott restated a buy rating on shares of BioDelivery Sciences International in a research report on Wednesday, November 13th. William Blair reiterated a buy rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. LADENBURG THALM/SH SH lifted their price objective on shares of BioDelivery Sciences International from $6.00 to $8.00 and gave the company a buy rating in a research note on Wednesday, November 13th. TheStreet raised shares of BioDelivery Sciences International from a d rating to a c rating in a research note on Friday, November 22nd. Finally, ValuEngine upgraded shares of BioDelivery Sciences International from a sell rating to a hold rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. BioDelivery Sciences International currently has an average rating of Buy and a consensus price target of $6.50.

Shares of NASDAQ BDSI traded down $0.06 during mid-day trading on Friday, reaching $6.43. The company had a trading volume of 950,325 shares, compared to its average volume of 975,441. The firm has a market cap of $575.63 million, a price-to-earnings ratio of -8.81 and a beta of 0.49. The business’s 50-day simple moving average is $6.00 and its 200 day simple moving average is $4.76. BioDelivery Sciences International has a one year low of $2.80 and a one year high of $7.01. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.02 and a current ratio of 2.25.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.34. The business had revenue of $30.31 million during the quarter, compared to analysts’ expectations of $28.86 million. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. On average, sell-side analysts anticipate that BioDelivery Sciences International will post 0.02 EPS for the current year.

In other news, CEO Herm Cukier sold 38,461 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.82, for a total value of $262,304.02. Following the completion of the transaction, the chief executive officer now owns 74,842 shares of the company’s stock, valued at $510,422.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Healthcare Master Fun Broadfin sold 2,206,243 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $6.04, for a total transaction of $13,325,707.72. The disclosure for this sale can be found here. Insiders sold 4,466,650 shares of company stock worth $26,391,760 over the last ninety days. 8.94% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of BDSI. Cutter & CO Brokerage Inc. acquired a new position in BioDelivery Sciences International during the 2nd quarter worth approximately $60,000. Metropolitan Life Insurance Co NY acquired a new stake in BioDelivery Sciences International in the third quarter valued at approximately $126,000. Nisa Investment Advisors LLC bought a new stake in shares of BioDelivery Sciences International during the third quarter worth $148,000. Resources Investment Advisors LLC. bought a new stake in shares of BioDelivery Sciences International during the second quarter worth $172,000. Finally, Acadian Asset Management LLC increased its holdings in shares of BioDelivery Sciences International by 348.9% during the second quarter. Acadian Asset Management LLC now owns 58,243 shares of the specialty pharmaceutical company’s stock worth $271,000 after buying an additional 45,269 shares in the last quarter. Institutional investors own 69.44% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: What are the qualifications of a portfolio manager?

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.